KPE 02001003
Alternative Names: KPE02001003; KPE02003002Latest Information Update: 18 Dec 2008
Price :
$50 *
At a glance
- Originator Kemin Pharma; National Institutes of Health (USA); Rega Institute for Medical Research
- Developer Kemin Pharma
- Class Antivirals; Small molecules
- Mechanism of Action Hepatitis C virus replication inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Hepatitis C
Most Recent Events
- 18 Dec 2008 No development reported - Phase-II for Hepatitis C in Belgium (unspecified route)
- 13 Jan 2005 KPE 02001003 is available for licensing worldwide (http://www.kemin.com)
- 15 Jan 2004 Phase-II clinical trials in Hepatitis C treatment in Belgium (unspecified route)